Glaxosmithkline

This study tested different doses of an injectable drug called GSK1070806 against a placebo in adults with moderate-to-severe atopic dermatitis (eczema). The main goal was to see how well the drug reduced the severity of skin rashes and itching over 16 weeks. Participants had pre…

This study aimed to evaluate the long-term safety and effectiveness of an investigational drug called GSK1070806 for adults with moderate-to-severe atopic dermatitis (eczema). It was an extension study for 79 participants who had already completed a previous trial of the same dru…

This study tested a new drug, GSK3915393, to see if it could slow the progression of idiopathic pulmonary fibrosis (IPF), a serious disease that causes permanent lung scarring and makes breathing difficult. About 158 people with IPF were randomly assigned to receive either the ne…

This early-stage study aimed to find a safe and effective dose of a two-drug combination (niraparib and dostarlimab) for children and adolescents whose solid tumors returned or did not respond to standard treatments. It involved 47 young participants with cancers like osteosarcom…

This early-stage study tested a new combination of therapeutic vaccines in adults with chronic Hepatitis B who were already taking antiviral pills. The main goals were to check the safety of the vaccines and see if they could help the body's immune system fight the virus and redu…

This was a very early, first-in-human study to check if a new oral drug called GSK4172239D was safe and how it moved through the body in people with sickle cell disease. Only 11 participants received a single dose of either the drug or a placebo. The study was terminated early, a…

This study tested an investigational drug, GSK3858279, to see if it could reduce chronic nerve pain in the hands and feet of adults with diabetes. About 150 participants were randomly assigned to receive either the drug or a placebo for 12 weeks to compare pain relief and safety.…

This study aimed to find the best dose of an experimental drug, GSK3858279, to relieve moderate to severe pain from knee osteoarthritis. It involved 314 adults aged 40-80 and compared different doses of the drug against a placebo over 12 weeks. The trial was terminated early, and…